
CTI BioPharma Corp. CTIC
Quartalsbericht 2023-Q1
hinzugefügt 15.05.2023
CTI BioPharma Corp. Langfristiger Schuldenstrom 2011-2026 | CTIC
Langfristiger Schuldenstrom Jährlich CTI BioPharma Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 781 K | 1.16 M | 2.19 M | 1.69 M | 4.81 M | 444 K | 7.95 M | 37.4 M | 9.01 M | 3.16 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 37.4 M | 444 K | 6.86 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Aptorum Group Limited
APM
|
433 K | $ 0.89 | - | $ 6.54 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 22.2 | - | $ 3.68 B | ||
|
Edesa Biotech
EDSA
|
19.9 K | $ 15.9 | - | $ 50.8 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Evogene Ltd.
EVGN
|
716 K | $ 0.76 | - | $ 27.9 M | ||
|
Exelixis
EXEL
|
27.9 M | $ 44.69 | - | $ 12.1 B | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Galapagos NV
GLPG
|
1.73 M | $ 27.86 | - | $ 2.69 B | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 7.91 | - | $ 6.83 B | ||
|
Harmony Biosciences Holdings
HRMY
|
1.07 M | $ 31.05 | - | $ 1.79 B | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
ImmuCell Corporation
ICCC
|
85.5 K | $ 8.44 | - | $ 76.2 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 101.57 | - | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Immuron Limited
IMRN
|
34.4 K | $ 0.81 | 0.3 % | $ 9.47 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Incyte Corporation
INCY
|
5.7 M | $ 99.1 | - | $ 19.3 B | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
InMed Pharmaceuticals
INM
|
376 K | $ 0.7 | - | $ 1.71 M | ||
|
INmune Bio
INMB
|
623 K | $ 1.33 | - | $ 32.9 M | ||
|
Innoviva
INVA
|
418 K | $ 23.05 | - | $ 1.55 B | ||
|
Jaguar Health
JAGX
|
192 K | $ 7.88 | - | $ 18.4 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
KalVista Pharmaceuticals
KALV
|
1.62 M | $ 26.67 | - | $ 1.44 B | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Kamada Ltd.
KMDA
|
2.12 M | $ 8.11 | - | $ 260 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 2.98 | - | $ 4.91 M | ||
|
Krystal Biotech
KRYS
|
1.77 M | $ 259.95 | - | $ 7.52 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
1.27 M | $ 224.86 | - | $ 4.11 B | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Liquidia Corporation
LQDA
|
900 K | $ 38.15 | - | $ 3.28 B | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.05 | - | $ 433 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M |